Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Total Current Liabilities (2016 - 2025)

Marimed (MRMD) has disclosed Total Current Liabilities for 15 consecutive years, with $56.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 26.88% to $56.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $56.6 million, a 26.88% increase, with the full-year FY2024 number at $50.0 million, up 62.03% from a year prior.
  • Total Current Liabilities was $56.6 million for Q3 2025 at Marimed, up from $50.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $56.6 million in Q3 2025 to a low of $14.6 million in Q1 2021.
  • A 5-year average of $34.2 million and a median of $30.9 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 58.01% in 2021, then soared 134.89% in 2022.
  • Marimed's Total Current Liabilities stood at $27.2 million in 2021, then decreased by 2.69% to $26.5 million in 2022, then rose by 16.5% to $30.9 million in 2023, then skyrocketed by 62.03% to $50.0 million in 2024, then grew by 13.15% to $56.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Total Current Liabilities are $56.6 million (Q3 2025), $50.9 million (Q2 2025), and $55.3 million (Q1 2025).